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Value Creation and R&D 
 
Apple and Dyson show us the importance of product innovation in creating values of firms. Such type 
of value creation happens when the products are actually in the market to generate cash. That is the 
fundamental value has been changed causes the value change, measured by share prices and dividends 
level changes. However, before the realisation of cash, the firms needed to spend a great deal on 
research and development (R&D) of the products. How should we report these R&D expenses in 
financial statements? How do investors see and react to the spending on R&D? Do they wait until 
they see the actual realisation of cash after the products are in the markets and then react, or they react 
straight away when they know a firm has spent a large amount of money on R&D? Would the capital 
markets react differently to different ways of reporting R&D costs?  
 
These are interesting questions that we attempt to address in this chapter. We first review the R&D 
accounting reporting requirements where R&D can be, in general, either written-off straight away in 
the Income Statement when it is incurred or capitalised as an asset on Statement of financial position. 
To capitalise it or not is an important question that the directors of companies need to think about. 
There are a number of conditions stipulated in the Accounting Standards to meet before the directors 
can decide to capitalise the R&D costs.  However, we argue that the subjective nature of the 
conditions of capitalisation provides a potential opportunity to the directors to communicate to 
investors whether something good is ahead. This is, of course, a pure hypothesis. We do not know 
whether the directors really use the capitalisation as a tool to signal or not. We do not know whether 
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the investors believe the signal or not. To look at this issue more deeply, we review the existing global 
empirical evidence reported in the literature.  
 
Through the literature review, we are in a better position to understand the practical signalling roles 
of R&D reporting. We also hope to identify some knowledge gaps that are still occurring in the 
literature as well as the inconsistencies found in the literature. This will in turn meet the major 
objective of this chapter which is to stimulate further research for both practitioners and academics to 
have an even better understanding of the value relevance of reporting R&D costs. 
 
 Financial Reporting Requirements 
 
On 19 July 2002, the European Parliament and the Council of the European Union passed Regulation 
(EC) No 1606/20021 which had as its primary objective the adoption and use of international 
accounting standards within the Community.  The regulation required publicly traded companies to 
adopt the use of international accounting standards in preparing their consolidated accounts for 
financial statements commencing on or after 1 January 2005. Article 2 of the regulation defines 
“international accounting standards” to include International Accounting Standards (IAS), 
International Financial Reporting Standards (IFRS) and related interpretations (SIC-IFRS 
interpretations).2 
 
The standard that is directly relevant to the discussion here is IAS 38 Intangible Assets3. The 
corresponding standards under UK General Accepted Accounting Principles (GAAP) are the 
Statement of Standard Accounting Practice (SSAP) 13 Accounting for Research and Development and 
FRS 10 Goodwill and Intangible Assets4.  However, as the discussion is primarily on R&D the focus 
will be on the requirements and application of SSAP 13. Furthermore, since 2005, the requirements 
under IAS 38 Intangible Assets have largely been followed and applied instead of the requirements of 
SSAP 135 The Standard, IAS 38 Intangible Assets, applies to all intangible assets except in instances 
where the accounting treatment, either due to the nature of the asset or the transaction underlying the 
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creation of the asset, is covered within the scope of another standard. An example, which is cited in 
the Standard would be, intangible assets held by an entity for the purposes of resale in the ordinary 
course of business should be treated in accordance with IAS 2 Inventories6.  
 
IAS 38 Intangible Assets establishes the general principles and criteria for the recognition and 
measurement of intangible assets. These principles and criteria are broadly similar to those under UK 
GAAP; however, there are some significant differences. SSAP 13 Accounting for Research and 
Development was originally issued in 1977 and revised in 1989, to provide guidance and establish the 
accounting practice to be followed in respect of research and development expenditure7. The basic 
concepts that underlie the determinations of the standard are the ‘accruals’ concept in relation to the 
matching of revenues and expenditures in the periods to which they were dealt with and the 
‘prudence’ concept in relation to the recognition of revenues and profits8 The scope and objectives of 
FRS 10 Goodwill and Intangible Assets are to set out the principles of accounting for goodwill and 
intangible assets9. The requirements of the Standard FRS 10 Goodwill and Intangible Assets apply to 
all intangible assets except those covered by SSAP 13 Accounting for Research and Development and 
within the scope of other standards10  
 
An intangible asset is defined by IAS 38 Intangible Assets as “an identifiable, non-monetary asset 
without physical substance”11. The main features of this definition are captured within the following 
components; 
 
 Identifiable (suggesting that it is separable or separately transferable); 
 Asset (the definition of which encompasses both the notions of future economic benefit and 
control) 
 
The significance of the ‘identifiable’ characteristic lies in the fact that the IASB has determined that 
all assets that are ‘separable’, as per above, are identifiable and thus in a business combination such 
assets should be recognised separately from goodwill. However, the standard states that the separable 
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nature of an asset in itself is not the only indication of it being identifiable as this criterion may be met 
in other ways, such as a legal right, giving rise to future economic benefit although not separable from 
the underlying business entity. However, it is the second component of the definition (an asset) that 
gives rise to the controversy surrounding this standard, for the determination of an asset – which is 
defined, essentially, by the ability to generate future economic benefit to the controlling entity - is 
rather uncertain and in many cases incorrectly forecasted when dealing with intangible assets. 
Intangible assets by their very nature present with a higher level of uncertainty pertaining to their 
ability to generate a future economic benefit than tangible assets.  For example, whereas it is 
relatively simple to quantify the potential earnings from a physical machine of a certain maximum 
production capacity which is being built, that is not always the case with the creation, say, of a new 
technology which is yet to be brought to market. The higher levels of uncertainty as exemplified 
above, can lead to either significant errors in estimation or may simply be abused or manipulated by 
managers who may have a biased opinion of the future viability of their intangible creations and its 
earnings potential. The suggestion is that, managers may use this opportunity not simply to inform 
investors of developments within the organisations but rather to give an overly optimistic view of the 
future earnings potential of the entities they manage, effectively using capitalisation as (or not) as a 
signal to the market about the future earnings potential of a firm. In an attempt to reduce the level of 
subjectivity in the exercise of determining what costs may be capitalised or not, the standard, 
introduces and invokes a set of stringent criteria to be applied in ascertaining whether R&D 
expenditure may be capitalised 
The term ‘research and development’ is used to describe a wide range of activities, SSAP 13 
Accounting for Research and Development defines research and development expenditure under three 
broad categories of activity, namely pure research, applied research and development. These 
categories are consistent with the Organisation for Economic Co-operation and Development’s 
(OECD) definition of the different types of research and development12. Pure research is defined as 
“work undertaken primarily to acquire new scientific or technical knowledge for its own sake…” 
whereas applied research is defined as “original or critical investigation undertaken in order to gain 
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new scientific or technical knowledge and directed towards a specific practical aim or objective”. 13 
However, such a distinction between pure and applied research is not made under IAS 38 Intangible 
Assets, instead the definition refers to research activities as being aimed at obtaining new knowledge 
and not related directly to any of the company’s products or processes14. However, both standards 
define development expenditure in broadly similar terms, with each requiring that a new and 
recognisable asset should be the outcome of such expenditure. Examples of such output given in the 
standard include, new materials, products, services or processes15. Essentially, R&D activity is 
identified separately from non-research based activity by the existence or otherwise of a substantial 
element of innovation or even the breaking of new ground. 
 
The accounting for R&D expenditure tends to fall into two broad treatments, namely; to write-off 
expenditure that is not directly attributable to the creation of an asset and to capitalise expenditure that 
does. SSAP 13 Accounting for Research and Development requires development expenditure to be 
written off except where the following stringent recognition criteria are met. This includes, the 
identification of a clearly defined project; separately identifiable expenditure and that the outcome of 
the project, in terms of its technical feasibility and commercial viability, can be measured or assessed 
with reasonable certainty and that sufficient resources exist to complete a profitable project16. Similar 
recognition criteria are provided under IAS 38 Intangible Assets, in that, if  it is probable that future 
economic benefit that are attributable to the asset will flow to the entity  and the costs of the asset can 
be measured reliably then it should be recognised in the financial statements17. On the other hand, 
research expenditure should be expensed as it is incurred; this is consistent with SSAP 13.  
 
The requirements for capitalisation under IAS 38 Intangible Assets are not dissimilar from those 
provided under SSAP 13 as noted above. However, the main difference is that under SSAP 13, 
development expenditure may be capitalised where the recognition criteria are met, whereas IAS 38 
requires capitalisation under similar circumstances, thus placing limits on management’s discretion18. 
It is the subjective nature of these criteria that has given rise to much debate over their application. 
Take for example, the identification of a clearly defined project; it is the directors (managers) of a 
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company who will invariably determine if a project is worth pursuing or not and only they have the 
full information to determine its technical feasibility and commercial viability. They could generate or 
compile sufficient accounting information which will enable them to satisfy the criteria for 
determining what costs are required to completion and prepare forecast of future incomes which 
confirm the profitability of the project. One could argue that directors’ being the holders of the fullest 
set of information pertaining to the project are best placed to make any judgements concerning the 
technical and commercial viability as well as the profitability of their projects. However, the very 
uncertain nature of such projects and the high levels of estimation which are invariably required in 
forecasting future costs and income will undoubtedly leave much space for subjective judgements. It 
is this space which is given to subjective judgments that allows for the possible manipulation and 
abuse of the very criteria set to limit management judgements. But if the directors can, and arguably 
should, make these judgements about the future viability of their projects, then market participants are 
equally likely to take a view as to the future earning potential of a firm based on the accounting 
treatment of its R&D costs. Therefore, by capitalising R&D expenditure, directors are communicating 
to market participants their judgements concerning the inherent and anticipated value of the current 
R&D expenditure. Likewise, an immediate write-off of similar expenditure would signal to the market 
the directors’ sentiments that the R&D expenditure to date had no capacity to generate future 
economic benefit. This effectively captures the signalling nature of the accounting treatment of R&D 
expenditure. 
 
Another important difference in accounting treatment that exists between UK GAAP and IFRS is in 
the treatment of internally generated intangible assets. Whereas IAS 38 has a single set of stringent 
rules to cover the recognition of internally generated assets under both development expenditure and 
other intangible assets, under UK GAAP, internally generated intangible assets may not normally be 
capitalised. The impact of this discrepancy in accounting treatment is that some assets which could 
not be recognised in the statement of financial position under UK GAAP will be capitalised under 
IAS 38. Interestingly, Tsoligkas and Tsalavoutas19, citing Green et al.,20, Stark and Thomas21 and 
Oswald22, note that under SSAP 13 and prior to 2005 many companies did not capitalise their R&D 
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expenditure. It would seem that the caution that directors took, even when faced with the potential to 
capitalise, has been eroded or completely removed by the change in requirement under IAS 38 for 
directors to capitalise their firms R&D costs once the criteria are met. By contrast, under US GAAP 
(SFAS No 2) all expenditure on R&D must be expensed in the income statement as the view taken by 
the US regulator is that ‘a direct relationship between research and development costs and 
specific future revenue’ has not been demonstrated23. 
This alternative view highlights a common underlying thread of concern in the minds of regulators as 
to the objectivity and reliability of estimates of R&D expenditure to be capitalised, and the associated 
opportunity for managers to manipulate earnings24  
 
We observe from the above that the accounting treatment of R&D expenditure is by no means the 
same across various parts of the world. However, where capitalisation is allowed or even required this 
tends to be a rather subjective exercise. It is precisely because of the subjective exercise, the ways in 
which to report R&D expenditure, that has generated some apposite debates in the literature of 
whether capitalisation signals something positive in the future? 
 
Review of global experience  
 
The last three decades have witnessed the unprecedented growth in R&D expenditure of which Apple 
and Dyson are recent examples from the US and UK respectively. Several authors (Garcia-Manjon 
and Romero-Merino25; Chan et al.26; Pyyko27) have all observed that R&D expenditure is the driver 
underlying corporate and even national growth. Pyyko, assesses the international impact of R&D 
expenditure and finds that it is the underlying driver for mergers and acquisition activity across 
international borders28. Garcia-Manjon and Romero-Merino, on the other hand find that the benefits 
of signalling applies mainly to high-technology firms and that R&D is only essential for the growth 




In this section, we review evidence from around the globe to establish if managers are able to use 
R&D expenditure reporting as a signal to the markets about the future earnings potential of their 
firms. The review begins with the case of the US, where under SFAS No. 2, firms are not allowed to 
capitalise R&D expenditure except in limited instances such as software development costs (SFAS 
No.86)30. Aboody and Lev31, cited in Eccher 32, conclude that whereas there is evidence that 
capitalising software costs, as a proxy for R&D capitalisation in the case of US firms, provides value-
relevant information about the future earnings potential of firms the accuracy of such forecasts is 
questionable. These findings are made all the more significant when one considers the FASB’s 
thinking behind the requirement to write to the income statement all R&D expenditure, that “a direct 
relationship between research and development costs and specific future revenue generally has not 
been demonstrated….”33 However, the fact that value-relevant information is provided, arguably at 
the expense of accuracy, does reopen the long standing debate on the trade-off between relevance and 
reliability which is also mentioned by Markarian et al34. The work by Aboody and Lev was prompted 
by the Software Publishers Associations (SPA) petition to the FASB in August 1996 to abolish SFAS 
No.8635. They argued that the capitalisation of software did not benefit the investor but rather if all 
software costs were charged to the income statement then the reliability and consistency of financial 
reporting and financial statements will be improved. These findings are at variance with conclusions 
drawn from the works of Sougiannis et al.,36; Lev and Sougiannis37 and Chambers et al., 38. 
Furthermore, Lev et al., find that the requirement to expense all R&D expenditure, may be costly to 
both the firms and market participants. The costs are incurred initially by the prevention of 
management to publish private inside information which would reduce information asymmetry 
between them and investors. This leads investor and other participants to seek this additional 
information through alternative and usually costly means. The lack of relevant information may also 
lead to the mispricing of equity and the associated inefficient allocation of resources39. 
 
In Europe, unlike the US, the implementation of IFRS means that firms are able and even required to 
capitalise their R&D expenditure where certain criteria are met. Following the study of some 754 
firms in Europe, Garcia-Manjon and Romero-Merino provide evidence to support a positive relation 
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between R&D and sales growth and conclude that for firms to increase their sales, grow and 
ultimately survive they must invest in R&D. They also find that the intensity of this relationship is 
enhanced in high-growth firms and heightened further in high-technology industries but this 
relationship is not clearly evidenced in low-technology firms40. This is consistent with the findings of 
Chan et al 41 and Zantout and Tsetsekos42 who also conclude that a strong positive correlation exists 
between R&D investment in high-technology industry firms and market responses and a negative 
correlation in the case of low-technology industry firms. 
 
Buckley and Casson43 and Caves44 are proponents of the internationalisation theory that suggests that 
cross-border M&A’s are largely driven by the benefits and synergies arising from the R&D activities 
of both the target and acquirer firms. Pyyko, extends the internationalisation theory using the ten most 
R&D active European countries and finds that “cross-border M&A’s have a positive impact on the 
value that investors place on acquirer’s R&D activity but only if both the acquirer and the target are 
technology ﬁrms”45 
 
The evidence from Italy provided by Markarian et al posits the notion that management’s motivation 
to capitalise R&D expenditure stems from the opportunity to use it as a tool for manipulating earnings 
or for earnings-management. Their work has contributed largely to the reliability side of the debate on 
the trade-off between relevance and reliability by identifying income-smoothing as being the 
determining factor for managers when considering whether to capitalise their R&D costs or not. They 
conclude that income-smoothing is an ‘effective and efficient way to signal and communicate 
important information to the market’ and so favour the requirement to expense all R&D costs if 
financial statements are to provide reliable information46. 
 
In the UK, the adoption of IFRS has had a positive impact on the value-relevance of reported assets 
with Tsoligkas and Tsalavoutas47 finding evidence in support of Barth et al48 and Ball49 that the 
implementation of IFRS improves the reporting of companies’ fundamentals. Reported R&D 
expenses though, were only found to be significantly value-relevant in large companies; this is in 
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contrast to the findings of Shah et al50 but consistent with Zhao51 Cazavan-Jeny and Jeanjean52. In 
other words, where large firms failed to capitalise their R&D expenditure this was perceived as 
inefficiency by investors. The assumption here being, that larger firms would be expected to make 
more efficient use of the R& D expenditure and gain a competitive technological advantage. 
 
Cazavan-Jeny and Jeanjean53, examine the value-relevance of R&D accounting treatment using a 
sample of companies listed in France. They conclude that capitalised R&D expenditure has a 
signalling effect evidenced by significant positive correlation with market prices for commercially 
successful firms and negatively correlated to the stock market returns or prices when R&D costs are 
expensed. However, Cazavan-Jeny and Jeanjean54 and Cazavan-Jeny et al55, find that capitalising 
R&D on the whole has a neutral or negative impact on future performance. ‘When firms both 
capitalise and expense R&D costs, the expensed portion exhibits a stronger (and negative) 
relationship with future earnings’. These findings are in stark contrast to the evidence reviewed 
previously which was largely in favour of capitalising R&D costs. 
 
 Value relevance of R&D reporting -gaps in knowledge 
 
Cazavan-Jeny et al, suggest possible reasons for the difference in their findings to previous evidence 
which was in support of capitalising R&D expenditure. One of the main reasons proffered for this 
difference is the fact that the research carried out by Cazavan-Jeny et al. was based on real data as 
opposed to simulated data which had been used previously56.  
 
Ahmed and Falk, make a similar point when reviewing their findings in the light of previous studies. 
This is particularly true of research based on US data where under FASB accounting rules companies 
must expense all their R&D costs. Therefore, researchers are required to make a judgement in placing 
all R&D expenditure into appropriate ‘capitalised’ and ‘expensed’ categories. The argument here is 
that manager’s, given the choice, may not capitalise the same expenditure, thus making these 




In countries where IFRS has been introduced, the adoption of IFRS has amplified companies’ 
fundamentals but continued to confirm the value relevance of R&D expenditure. This is particularly 
evident in countries like the UK where the accounting treatment has not changed significantly from 
pre-2005. What is not clear is what the impact would have been if the accounting treatment had 
changed significantly from pre-200558. 
 
The studies by Garcia-Manjon and Romero-Merino, Chan et al and Zantout and Tsetsekos suggest 
that the type of industry (high-technology or low technology) and Ehie and Olibie the type of sector 
(manufacturing or service) will have a bearing on outcomes. Firms in the high-technology industry are 
more likely to benefit disproportionately from the effects of R&D expenditure as compared to low 
technology firms59. 
 
Chambers60 citing Ciftci et al61, suggests that given the uncertain nature of the future earnings from 
R&D expenditure, firms involved in an innovative R&D strategy may find their stock mis-priced 
(generally under-priced) due to the anticipated and associated inherent risk in the R&D projects and a 
conservative estimate of expected future earnings. 
 
5. Summary and Conclusion 
 
The two main accounting treatments are to either expense the R&D costs to the income statement or 
to capitalise R&D expenditure in the statement of financial position. In certain contexts, such as in the 
US, the accounting treatment is quite prescriptive with little or no room for management judgement. 
The required accounting treatment under US GAAP is to expense all R&D costs, as the standard-
setter’s claim there is no demonstrable relationship between R&D costs and specific future revenue. A 
considerable amount of research has been performed across the globe to provide evidence that a 
relationship does exist between R&D costs and specific future revenue. It is in the face of this 
mounting evidence that other standard-setters in the UK, Italy and France (pre-2005) and now 
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throughout Europe, under IFRS, not only allow for the capitalisation of R&D expenditure but also 
require it where the conditions for capitalisation are met. It is these conditions for capitalisation that 
have been the subject of much debate as they are largely of a subjective nature and require a certain 
amount of management discretion. Much of the debate has centred on the value-relevance of the 
amounts recognised in the financial statements as either an expense or an asset and whether or not 
management are inclined to use R&D expenditure as a tool to signal to the capital markets the future 
earnings potential of their companies. 
 
The evidence suggests that, investors’ perceive firms that expense their R&D costs negatively 
whereas those firms that capitalise their R&D expenditure tend to see a positive reaction to their stock 
prices. This positive correlation between the capitalisation of R&D expenditure and market responses 
is further enhanced in high-growth and high-technology firms. Larger firms also tended to benefit 
relatively more due to the perceived efficiencies and synergies. However, a fundamental problem that 
pervaded the findings was that although there was a positive correlation between the capitalisation of 
R&D costs and market responses, the estimation of the perceived benefits or forecast of future 
earnings fell short of the reality.  
 
However, a recent study by Cazavan-Jeny et al, based on a sample of French listed companies, found 
evidence that capitalising R&D on the whole has a neutral or negative impact on future performance. 
These findings are in stark contrast to the evidence reviewed earlier which was in favour of assertion 
that capitalising R&D costs invariably leads to increases in market values. 
 
These conflicting empirical findings mean that it is difficult to conclude the value relevance of 
accounting treatment to R&D expenditure despite in theory that capitalisation of the expenditure has 
signalling value of a good future. It is safe to say that more research is required to work out where the 
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